See more : East Africa Metals Inc. (EAM.V) Income Statement Analysis – Financial Results
Complete financial analysis of MedMen Enterprises Inc. (MMNFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MedMen Enterprises Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Siltronic AG (WAF1.DE) Income Statement Analysis – Financial Results
- PT Mark Dynamics Indonesia Tbk (MARK.JK) Income Statement Analysis – Financial Results
- Nintendo Co., Ltd. (7974.T) Income Statement Analysis – Financial Results
- Akzo Nobel N.V. (AKZOY) Income Statement Analysis – Financial Results
- Hermana Holding ASA (HERMA.OL) Income Statement Analysis – Financial Results
MedMen Enterprises Inc. (MMNFF)
About MedMen Enterprises Inc.
MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, distributes, and retails recreational and medicinal cannabis under the MedMen Red and LuxLyte brand names. As of December 25, 2021, it operated 29 stores in California, Florida, Nevada, Illinois, Arizona, Massachusetts, and New York. MedMen Enterprises Inc. is headquartered in Culver City, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 140.81M | 145.07M | 157.11M | 129.96M | 39.78M | 2.67M | 20.07K | 26.65K | 20.64K | 24.92K | 19.66K | 27.66K | 18.14K | 33.60K | 36.42K | 22.18K | 20.28K | 19.34K | 30.11K | 0.00 | 305.46K |
| Cost of Revenue | 71.08M | 77.78M | 98.99M | 69.09M | 25.93M | 1.80M | 7.89K | 7.66K | 7.96K | 7.78K | 9.02K | 10.70K | 9.33K | 10.32K | 9.36K | 10.82K | 8.19K | 7.78K | 19.30K | 0.00 | 395.02K |
| Gross Profit | 69.73M | 67.29M | 58.12M | 60.88M | 13.85M | 868.14K | 12.18K | 19.00K | 12.69K | 17.14K | 10.63K | 16.96K | 8.81K | 23.28K | 27.06K | 11.36K | 12.08K | 11.56K | 10.81K | 0.00 | -89.56K |
| Gross Profit Ratio | 49.52% | 46.39% | 36.99% | 46.84% | 34.81% | 32.49% | 60.69% | 71.27% | 61.46% | 68.78% | 54.09% | 61.32% | 48.56% | 69.30% | 74.31% | 51.23% | 59.59% | 59.76% | 35.90% | 0.00% | -29.32% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 108.72M | 124.59M | 200.27M | 234.65M | 98.18M | 14.14M | 136.18K | 240.61K | 133.04K | 236.99K | 53.70K | 28.22K | 41.69K | 41.73K | 11.11K | 8.91K | 9.37K | 19.11K | 45.59K | 0.00 | 0.00 |
| Selling & Marketing | 3.21M | 1.11M | 10.64M | 27.55M | 7.01M | 323.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 111.93M | 125.70M | 210.92M | 262.20M | 105.20M | 14.46M | 136.18K | 240.61K | 133.04K | 236.99K | 53.70K | 28.22K | 41.69K | 41.73K | 11.11K | 8.91K | 9.37K | 19.11K | 45.59K | 74.82K | 171.76K |
| Other Expenses | 19.10M | 30.89M | 39.95M | 20.98M | 5.26M | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 216.33K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 131.03M | 156.59M | 250.87M | 283.17M | 110.45M | 15.66M | 136.18K | 240.61K | 133.04K | 236.99K | 53.70K | 28.22K | 41.69K | 41.73K | 11.11K | 8.91K | 9.37K | 19.11K | 45.59K | 74.82K | 179.99K |
| Cost & Expenses | 202.11M | 234.37M | 349.86M | 352.26M | 136.39M | 17.46M | 144.07K | 248.26K | 140.99K | 244.77K | 62.73K | 38.92K | 51.02K | 52.05K | 20.47K | 19.73K | 17.56K | 26.90K | 64.89K | 74.82K | 575.01K |
| Interest Income | 91.59K | 649.23K | 766.04K | 701.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 43.07M | 61.37M | 49.49M | 22.82M | 16.11M | 512.44K | 135.37 | 6.53K | 2.46K | 30.07K | 35.41K | 34.97K | 35.93K | 30.44K | 37.00K | 31.38K | 29.77K | 17.16K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 25.74M | 34.46M | 43.71M | 23.54M | 5.15M | 1.57M | 22.82K | 6.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 216.33K | 0.00 | 10.08K | 0.00 | 0.00 |
| EBITDA | -35.56M | -54.84M | -149.04M | -198.75M | -91.45M | -13.22M | -124.01K | -221.61K | -120.35K | -219.85K | -43.07K | -11.26K | -32.88K | -18.45K | 15.95K | 2.45K | 219.04K | -7.55K | -24.71K | -74.82K | -269.55K |
| EBITDA Ratio | -25.26% | -37.81% | -94.86% | -152.93% | -229.87% | -494.85% | -618.00% | -831.49% | -582.98% | -882.08% | -219.12% | -40.73% | -181.26% | -54.90% | 43.80% | 11.04% | 1,080.18% | -39.05% | -82.07% | 0.00% | -88.24% |
| Operating Income | -61.30M | -89.30M | -192.75M | -222.30M | -96.60M | -14.79M | -124.01K | -228.14K | -120.35K | -219.85K | -43.07K | -11.26K | -32.88K | -18.45K | 15.95K | 2.45K | 2.72K | -7.55K | -34.79K | -74.82K | -269.55K |
| Operating Income Ratio | -43.53% | -61.56% | -122.68% | -171.05% | -242.83% | -553.54% | -618.00% | -855.98% | -582.98% | -882.08% | -219.12% | -40.73% | -181.26% | -54.90% | 43.80% | 11.04% | 13.40% | -39.05% | -115.55% | 0.00% | -88.24% |
| Total Other Income/Expenses | -114.15M | -67.40M | -328.92M | -22.30M | -11.01M | -2.91M | -18.81 | 0.00 | -2.46K | -30.07K | -35.41K | -34.97K | -35.93K | -30.44K | -37.00K | -31.38K | 186.55K | -17.16K | 360.22K | 0.00 | -1.00M |
| Income Before Tax | -175.45M | -143.61M | -515.35M | -263.23M | -110.73M | -15.38M | -124.14K | -228.14K | -122.80K | -249.92K | -78.48K | -46.23K | -68.81K | -48.88K | -21.05K | -28.93K | 189.27K | -24.72K | 325.43K | 0.00 | -1.27M |
| Income Before Tax Ratio | -124.60% | -99.00% | -328.01% | -202.54% | -278.32% | -575.46% | -618.67% | -855.98% | -594.87% | -1,002.74% | -399.26% | -167.16% | -379.31% | -145.49% | -57.81% | -130.46% | 933.37% | -127.80% | 1,080.98% | 0.00% | -416.30% |
| Income Tax Expense | -9.90M | 1.83M | -39.60M | 13.81M | 1.54M | 43.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.77K | 0.00 | 0.00 | 75.18K | 0.00 |
| Net Income | -165.55M | -145.45M | -475.75M | -277.05M | -112.26M | -15.42M | -124.14K | -228.14K | -122.80K | -249.92K | -78.48K | -46.23K | -68.81K | -48.88K | -21.05K | -28.93K | 189.27K | -24.72K | 325.43K | -75.18K | -1.27M |
| Net Income Ratio | -117.57% | -100.26% | -302.81% | -213.17% | -282.19% | -577.07% | -618.67% | -855.98% | -594.87% | -1,002.74% | -399.26% | -167.16% | -379.31% | -145.49% | -57.81% | -130.46% | 933.37% | -127.80% | 1,080.98% | 0.00% | -416.30% |
| EPS | -0.14 | -0.27 | -1.76 | -2.62 | -2.77 | -26.33 | -0.21 | -0.56 | -0.50 | -0.93 | -1.76 | -1.03 | -1.54 | -1.09 | -0.47 | -0.65 | 4.24 | -0.55 | 7.28 | -1.68 | -28.73 |
| EPS Diluted | -0.14 | -0.27 | -1.76 | -2.62 | -2.77 | -26.33 | -0.21 | -0.56 | -0.50 | -0.93 | -1.76 | -1.03 | -1.54 | -1.09 | -0.47 | -0.65 | 4.24 | -0.55 | 7.28 | -1.68 | -28.73 |
| Weighted Avg Shares Out | 1.15B | 530.98M | 270.42M | 105.92M | 40.48M | 585.58K | 585.58K | 410.57K | 245.24K | 268.30K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.26K |
| Weighted Avg Shares Out (Dil) | 1.15B | 530.98M | 270.42M | 105.92M | 40.48M | 585.58K | 585.58K | 410.57K | 245.24K | 268.30K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.26K |
MedMen Enters into Definitive Agreements to Exit Arizona and Nevada per Announced Strategic Review, Selling Non-Core Assets to MINT Cannabis
BOCA RATON, Fla.--(BUSINESS WIRE)--MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier cannabis company with operations across the United States, today announced that it has entered into definitive agreements to sell its non-core business operations in...
MedMen Provides Annual Filing Status Report
BOCA RATON, Fla.--(BUSINESS WIRE)--MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier cannabis company with operations across the United States, is providing this bi-weekly default status report in accordance with National Policy 12-203 – Management Cease...
MedMen Provides Annual Filing Status Report
LOS ANGELES--(BUSINESS WIRE)--MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier cannabis company with operations across the United States, is providing this bi-weekly default status report in accordance with National Policy 12-203 – Management Cease Trade...
Cannabis Cash Burn Concerns? Sell These 7 Overbought Stocks Now.
The rollercoaster ride of the cannabis market has left many in the investing world dazed and confused. The sector's volatility is marked by winds of optimism followed by spells of disappointment.
MedMen Announces Delay of Filing of Financial Statements for the Year Ended July 1, 2023 and Issuance of Management Cease Trade Order
LOS ANGELES--(BUSINESS WIRE)--MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier cannabis company with operations across the United States, today announced it expects to be late in filing its financial statements and management's discussion and analysis...
Reasons To Be Cautiously Optimistic About Cannabis
Cautious optimism is warranted in the cannabis industry due to potential changes, such as the move to federal legalization and improved fundamentals. Investors should consider their risk appetite, timeframes, and political catalysts when choosing cannabis companies to invest in.
Ticking Time Bombs: 3 Cannabis Stocks to Dump Before the Damage Is Done
The North American cannabis market is booming in 2023, thanks to the legalization of recreational and medical marijuana in several states and provinces. Many investors are betting on the growth potential of this industry, especially as cannabis may be moved...
The Sustainability Of Cannabis Bull Run
The DEA is considering reclassifying cannabis from Schedule I to Schedule III, leading to a surge in cannabis stocks. Reclassification could lead to tax breaks, access to banking services, and more efficient logistics for the cannabis industry. Profitable cannabis companies,...
Year-to-Date Winners: Top Marijuana Penny Stocks to Keep on Your Radar
The top marijuana stocks have emerged as lucrative possibilities in the volatile world of cannabis investments, with spectacular increases year to year. These green stock market treasures have piqued the interest of investors looking for chances in the thriving cannabis...
Top Marijuana Penny Stocks to Watch in August 2023
Welcome to the intriguing world of marijuana penny stocks! As we approach August 2023, the cannabis sector is witnessing rapid growth and drawing investors looking to cash in on the green revolution. Penny stock trading can be exciting and risky;...
Source: https://incomestatements.info
Category: Stock Reports